Method of Increasing Efficacy of Tumor-Cell Killing Using Combinations of Anti-Neoplastic Agent
- Technology Application
- Through use of the present invention, ineffective treatment regimens can be avoided in certain sub-populations of patients suffering from neoplastic diseases, effective treatment regimens can be instituted for patients who were previously refractive to certain treatments, and an overall improvement in anti-neoplastic therapies can be achieved.
- Detailed Technology Description
- Researchers at UC San Diego have developed a method of improving the killing efficacy of treatments for neoplasias using CD33-binding agents. This technology achieves the improvement by treating a patient with a substance that increases the amount of active Syk protein and/or SHP-l protein in the target neoplastic cells before or during treatment with an agent that specifically binds the CD33 protein.
- Supplementary Information
- Patent Number: US7977320B2
Application Number: US2007718127A
Inventor: Ball, Edward D. | Balaian, Larissa
Priority Date: 29 Oct 2004
Priority Number: US7977320B2
Application Date: 30 Jul 2007
Publication Date: 12 Jul 2011
IPC Current: A01N004304 | A61K003170
US Class: 514043 | 514042 | 514045 | 514049
Assignee Applicant: The Regents of the University of California
Title: Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents
Usefulness: Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents
Summary: For increasing efficacy of cell-killing agent useful for treating neoplasia e.g. leukemia such as acute myeloid leukemia (AML) (claimed).
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Cancer/Tumor
- Application No.
- 7977320
- Others
-
Intellectual Property Info
Patented technology (U.S. patent application, published 20-Mar-2008 (2008/0069818), includes the following allowed claims:
A method of increasing the efficacy of a cell-killing agent on a neoplastic cell that expresses CD33, said method comprising:
exposing the neoplastic cell to a substance that increases the amount of functional Syk protein kinase, SHP-1 protein phosphatase, or both, in the neoplastic cell, determining the presence or activity level of said Syk protein, SHP-1 protein, or both in said neoplastic cell in response to the exposure, wherein the presence or level of active Syk protein, SHP-1 protein, or both is indicative of a likelihood of successful treatment of a neoplasia with said cell-killing agent, and recommending administering a therapeutically effective amount of said cell-killing agent based upon the determination of the presence or activity of said Syk protein, SHP-1 protein, or both in said neoplastic cell, thereby increasing the efficacy of the cell-killing agent on the neoplastic cell.
A method of treating a neoplasia, said method comprising:
administering at least one substance that increases the amount of functional Syk protein kinase, SHP-1 protein phosphatase, or both, in at least one cell of the neoplasia, determining the presence or activity level of said Syk protein kinase, SHP-1 protein phosphatase, or both, in said neoplastic cell in response to administration of said substance to said cell; and providing information about the determination for clinical administration of a therapeutically effective amount of at least one cell-killing agent based upon the presence or activity of said Syk protein, SHP-1 protein, or both in said neoplastic cell.
A method of treating a patient for a neoplasia characterized by cells that express CD33, said method comprising:
obtaining the amount or activity state of the Syk protein kinase, SHP-1 protein phosphatase, or both, in at least one neoplastic cell of the neoplasia, and providing a treatment regimen based on the amount or activity state that is determined for clinical administration of a therapeutically effective amount of a cell-killing agent that targets CD33 based upon the amount or activity state of the Syk protein kinase, SHP-1 protein phosphatase, or both, in said neoplastic cell of the neoplasia.
Tech ID/UC Case
21417/2005-062-0
Related Cases
2005-062-0
- *Abstract
-
It has been found that certain neoplastic cells expressing relatively high levels of active Syk protein and/or active SHP-l protein are more susceptible to killing by agents that target CD33 than cells not expressing the active forms of these proteins. This discovery has lead to the realization that treatment of tumor cells with agents that increase the expression of Syk and/or SHP-l, or that increase the amount of active Syk and/or SHP-l in a neoplastic cell, can improve the efficacy of treatments that target protein activation cascades in which these proteins are members, such as those involving ligation of the cell-surface protein CD33.
- *IP Issue Date
- Jul 12, 2011
- *Principal Investigator
-
Name: Larisa Balaian
Department:
Name: Edward Ball
Department:
- Country/Region
- USA
